(Q41781931)

9 October 2017

Prognostic factors in patients with hepatitis B virus-related hepatocellular carcinoma undergoing nucleoside analog antiviral therapy (English)

1 reference

9 October 2017

1 reference

Hiroki Nishikawa

1

1 reference

9 October 2017

Norihiro Nishijima

2

1 reference

9 October 2017

Akira Arimoto

3

1 reference

9 October 2017

Tadashi Inuzuka

4

1 reference

9 October 2017

Ryuichi Kita

5

1 reference

9 October 2017

Toru Kimura

6

1 reference

9 October 2017

Yukio Osaki

7

1 reference

9 October 2017

12 September 2013

1 reference

9 October 2017

1 reference

9 October 2017

6

1 reference

9 October 2017

5

1 reference

9 October 2017

1213-1218

1 reference

Effects of antiviral therapy on the recurrence of hepatocellular carcinoma after curative resection or liver transplantation.

9 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Epidemiology of viral hepatitis and hepatocellular carcinoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

6 June 2018

Hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Hepatitis B virus resistance to antiviral drugs: where are we going?

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Loco-regional treatment of hepatocellular carcinoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Combination therapy of lamivudine and adefovir in Japanese patients with chronic hepatitis B

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

NIH consensus development statement on management of hepatitis B.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Hepatocellular carcinoma and hepatitis B virus

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Management of hepatocellular carcinoma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Effect of transcatheter arterial chemoembolization prior to surgical resection for hepatocellular carcinoma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3813761

A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma

18 August 2018

1 reference

12 December 2020

Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma

1 reference

12 December 2020

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

12 December 2020

High serum hyaluronic acid and HBV viral load are main prognostic factors of local recurrence after complete radiofrequency ablation of hepatitis B-related small hepatocellular carcinoma

1 reference

12 December 2020

Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization

1 reference

12 December 2020

Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma

1 reference

12 December 2020

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients

1 reference

12 December 2020

Treatment of chronic hepatitis B with nucleos(t)ide analogues

1 reference

12 December 2020

The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan

1 reference

12 December 2020

Identifiers

DOI

10.3892/OL.2013.1578

1 reference

release_7wgwkw5aczfhbotvw26qezpdmi

9 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7wgwkw5aczfhbotvw26qezpdmi

24 November 2022

mapped directly with Wikidata item

1 reference

9 October 2017

PubMed publication ID

24179497

1 reference